Qi Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Qi Zhou has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Hongbin Lv
The Affiliated Hospital of Southwest Medical University
2 shared publications - Jingliang Cheng
Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan, China
2 shared publications - Junjiang Fu
Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, China
2 shared publications - Asaduzzaman Khan
The Research Centre for Preclinical Medicine, Southwest Medical University, Luzhou, People’s Republic of China
1 shared publication Chengxia Duan
Department of Ophthalmology, Affiliated Hospital of Luzhou Medical College, Luzhou, Sichuan 646000, China
1 shared publication- Chunli Wei
Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 5401760
Protective Effect and Possible Mechanisms of Artemisinin and Its Derivatives for Diabetic Nephropathy: A Systematic Review and Meta‐Analysis in Animal Models
Background. Artemisinin and its derivatives have potential antidiabetic effects. There is no evaluation of reported studies in the literature on the treatment of diabetic nephropathy (DN), one of the commonest diabetic microangiopathies, with artemisinins. Here, we aimed to evaluate preclinical evidence for the efficacy and possible mechanisms of artemisinins in reducing diabetic renal injury. Methods. We conducted an electronic literature search in fourteen databases from their inception to November 2021. All animal studies assessing the efficacy and safety of artemisinins in DN were included, regardless of publication or language. Overall, 178 articles were screened according to predefined inclusion and exclusion criteria. Finally, 18 eligible articles were included in this systematic review. The SYstematic Review Center for Laboratory animal Experimentation (SYRCLE) risk‐of‐bias tool was used to assess the risk of bias in the included studies. The primary outcomes were kidney function, proteinuria, and renal pathology. Secondary endpoints included changes in fasting plasma glucose (FPG) levels, body weight, and relevant mechanisms. Results. Of the 18 included articles involving 418 animal models of DN, 1, 2, 6, and 9 used dihydroartemisinin, artemether, artesunate, and artemisinin, respectively. Overall, artemisinins reduced indicators of renal function, including blood urea nitrogen (P < 0.00001), serum creatinine (P < 0.00001), and kidney index (P = 0.0001) compared with control group treatment. Measurements of proteinuria (P < 0.00001), microalbuminuria (P < 0.05), and protein excretion (P = 0.0002) suggested that treatment with artemisinins reduced protein loss in animals with DN. Artemisinins may lower blood glucose levels (P = 0.01), but there is a risk of weight gain (P < 0.00001). Possible mechanisms of action of artemisinins include delaying renal fibrosis, reducing oxidative stress, and exerting antiapoptotic and anti‐inflammatory effects. Conclusion. Available evidence suggests that artemisinins may be protective against renal injury secondary to diabetes in preclinical studies; however, high‐quality and long‐term trials are needed to reliably determine the balance of benefits and harms.
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 5401760
Open AccessProtective Effect and Possible Mechanisms of Artemisinin and Its Derivatives for Diabetic Nephropathy: A Systematic Review and Meta‐Analysis in Animal Models
Background. Artemisinin and its derivatives have potential antidiabetic effects. There is no evaluation of reported studies in the literature on the treatment of diabetic nephropathy (DN), one of the commonest diabetic microangiopathies, with artemisinins. Here, we aimed to evaluate preclinical evidence for the efficacy and possible mechanisms of artemisinins in reducing diabetic renal injury. Methods. We conducted an electronic literature search in fourteen databases from their inception to November 2021. All animal studies assessing the efficacy and safety of artemisinins in DN were included, regardless of publication or language. Overall, 178 articles were screened according to predefined inclusion and exclusion criteria. Finally, 18 eligible articles were included in this systematic review. The SYstematic Review Center for Laboratory animal Experimentation (SYRCLE) risk‐of‐bias tool was used to assess the risk of bias in the included studies. The primary outcomes were kidney function, proteinuria, and renal pathology. Secondary endpoints included changes in fasting plasma glucose (FPG) levels, body weight, and relevant mechanisms. Results. Of the 18 included articles involving 418 animal models of DN, 1, 2, 6, and 9 used dihydroartemisinin, artemether, artesunate, and artemisinin, respectively. Overall, artemisinins reduced indicators of renal function, including blood urea nitrogen (P < 0.00001), serum creatinine (P < 0.00001), and kidney index (P = 0.0001) compared with control group treatment. Measurements of proteinuria (P < 0.00001), microalbuminuria (P < 0.05), and protein excretion (P = 0.0002) suggested that treatment with artemisinins reduced protein loss in animals with DN. Artemisinins may lower blood glucose levels (P = 0.01), but there is a risk of weight gain (P < 0.00001). Possible mechanisms of action of artemisinins include delaying renal fibrosis, reducing oxidative stress, and exerting antiapoptotic and anti‐inflammatory effects. Conclusion. Available evidence suggests that artemisinins may be protective against renal injury secondary to diabetes in preclinical studies; however, high‐quality and long‐term trials are needed to reliably determine the balance of benefits and harms.
- Open Access
- 9 December 2021
- Published by Springer Nature in Research Square
Identification of Methylated Differentially Expressed Hub Genes and Immune Infiltration in Diabetic Retinopathy
BackgroundDiabetic retinopathy (DR), a severe complication of diabetes mellitus (DM), is a global social and economic burden. However, the pathological mechanisms mediating DR are not well-understood. This study aimed to identify differentially methylated and differentially expressed hub genes (DMGs and DEGs, respectively) and associated signaling pathways, and to evaluate immune cell infiltration involved in DR. MethodsTwo publicly available datasets were downloaded from the Gene Expression Omnibus database. Transcriptome and epigenome microarray data and multi-component weighted gene coexpression network analysis (WGCNA) were utilized to determine hub genes within DR. One dataset was utilized to screen DEGs and to further explore their potential biological functions using functional annotation analysis. A protein-protein interaction network was constructed. Gene set enrichment and variation analyses (GSVA and GSEA, respectively) were utilized to identify the potential mechanisms mediating the function of hub genes in DR. Infiltrating immune cells were evaluated in one dataset using CIBERSORT. The Connectivity Map (CMap) database was used to predict potential therapeutic agents. ResultsIn total, 673 DEGs (151 upregulated and 522 downregulated genes) were detected. Gene expression was significantly enriched in the extracellular matrix and sensory organ development, extracellular matrix organization, and glial cell differentiation pathways. Through WGCNA, one module was found to be significantly related with DR (r=0.34, P =0.002), and 979 hub genes were identified. By comparing DMGs, DEGs, and genes in WGCNA, we identified eight hub genes in DR ( AKAP13, BOC, ACSS1, ARNT2, TGFB2, LHFPL2, GFPT2, TNFRSF1A ), which were significantly enriched in critical pathways involving coagulation, angiogenesis, TGF-β, and TNF-α-NF-κB signaling via GSVA and GSEA. Immune cell infiltration analysis revealed that activated natural killer cells, M0 macrophages, resting mast cells, and CD8 + T cells may be involved in DR. ARNT2, TGFB2, LHFPL2 , and AKAP13 expression were correlated with immune cell processes, and ZG-10, JNK-9L, chromomycin-a3, and calyculin were identified as potential drugs against DR. Finally, TNFRSF1A , GFPT2 , and LHFPL2 expression levels were consistent with the bioinformatic analysis. ConclusionsOur results are informative with respect to correlations between differentially methylated and expressed hub genes and immune cell infiltration in DR, providing new insight towards DR drug development and treatment.
- 9 December 2021
- Published by Springer Nature in Research Square
Open AccessIdentification of Methylated Differentially Expressed Hub Genes and Immune Infiltration in Diabetic Retinopathy
BackgroundDiabetic retinopathy (DR), a severe complication of diabetes mellitus (DM), is a global social and economic burden. However, the pathological mechanisms mediating DR are not well-understood. This study aimed to identify differentially methylated and differentially expressed hub genes (DMGs and DEGs, respectively) and associated signaling pathways, and to evaluate immune cell infiltration involved in DR. MethodsTwo publicly available datasets were downloaded from the Gene Expression Omnibus database. Transcriptome and epigenome microarray data and multi-component weighted gene coexpression network analysis (WGCNA) were utilized to determine hub genes within DR. One dataset was utilized to screen DEGs and to further explore their potential biological functions using functional annotation analysis. A protein-protein interaction network was constructed. Gene set enrichment and variation analyses (GSVA and GSEA, respectively) were utilized to identify the potential mechanisms mediating the function of hub genes in DR. Infiltrating immune cells were evaluated in one dataset using CIBERSORT. The Connectivity Map (CMap) database was used to predict potential therapeutic agents. ResultsIn total, 673 DEGs (151 upregulated and 522 downregulated genes) were detected. Gene expression was significantly enriched in the extracellular matrix and sensory organ development, extracellular matrix organization, and glial cell differentiation pathways. Through WGCNA, one module was found to be significantly related with DR (r=0.34, P =0.002), and 979 hub genes were identified. By comparing DMGs, DEGs, and genes in WGCNA, we identified eight hub genes in DR ( AKAP13, BOC, ACSS1, ARNT2, TGFB2, LHFPL2, GFPT2, TNFRSF1A ), which were significantly enriched in critical pathways involving coagulation, angiogenesis, TGF-β, and TNF-α-NF-κB signaling via GSVA and GSEA. Immune cell infiltration analysis revealed that activated natural killer cells, M0 macrophages, resting mast cells, and CD8 + T cells may be involved in DR. ARNT2, TGFB2, LHFPL2 , and AKAP13 expression were correlated with immune cell processes, and ZG-10, JNK-9L, chromomycin-a3, and calyculin were identified as potential drugs against DR. Finally, TNFRSF1A , GFPT2 , and LHFPL2 expression levels were consistent with the bioinformatic analysis. ConclusionsOur results are informative with respect to correlations between differentially methylated and expressed hub genes and immune cell infiltration in DR, providing new insight towards DR drug development and treatment.
- Open Access
- 2 June 2020
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 40 (6)
Novel compound heterozygous EYS variants may be associated with arRP in a large Chinese pedigree
As a genetically heterogeneous ocular dystrophy, gene mutations with autosomal recessive retinitis pigmentosa (arRP) in patients have not been well described. We aimed to detect the disease-causing genes and variants in a Chinese arRP family. In this study, a large Chinese pedigree consisting of 31 members including a proband and another two patients was recruited; clinical examinations were conducted; next-generation sequencing using a gene panel was used for identifying pathogenic genes and Sanger sequencing was performed for verification of mutations. Novel compound heterozygous variants c.G2504A (p.C835Y) and c.G6557A (p.G2186E) for the EYS gene were identified, which co-segregated with the clinical RP phenotypes. Sequencing of 100 ethnically matched normal controls didn’t found these mutations in EYS. Therefore, our study identified pathogenic variants in EYS that may cause arRP in this Chinese family. This is the first study to reveal the novel mutation in the EYS gene (c.G2504A, p.C835Y), extending its mutation spectrum. Thus, the EYS c.G2504A (p.C835Y) and c.G6557A (p.G2186E) variants may be the disease-causing missense mutations for RP in this large arRP family. These findings should be helpful for molecular diagnosis, genetic counseling and clinical management of arRP disease.
- 2 June 2020
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 40 (6)
Open AccessNovel compound heterozygous EYS variants may be associated with arRP in a large Chinese pedigree
As a genetically heterogeneous ocular dystrophy, gene mutations with autosomal recessive retinitis pigmentosa (arRP) in patients have not been well described. We aimed to detect the disease-causing genes and variants in a Chinese arRP family. In this study, a large Chinese pedigree consisting of 31 members including a proband and another two patients was recruited; clinical examinations were conducted; next-generation sequencing using a gene panel was used for identifying pathogenic genes and Sanger sequencing was performed for verification of mutations. Novel compound heterozygous variants c.G2504A (p.C835Y) and c.G6557A (p.G2186E) for the EYS gene were identified, which co-segregated with the clinical RP phenotypes. Sequencing of 100 ethnically matched normal controls didn’t found these mutations in EYS. Therefore, our study identified pathogenic variants in EYS that may cause arRP in this Chinese family. This is the first study to reveal the novel mutation in the EYS gene (c.G2504A, p.C835Y), extending its mutation spectrum. Thus, the EYS c.G2504A (p.C835Y) and c.G6557A (p.G2186E) variants may be the disease-causing missense mutations for RP in this large arRP family. These findings should be helpful for molecular diagnosis, genetic counseling and clinical management of arRP disease.
- 10 February 2020
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 46 (5) , 684-693
Sequence variant in the CDC42BPB gene is potentially associated with Mullerian duct anomalies
Aim Mullerian duct anomalies (MDA) are common female genital tract malformations. Genetic and environmental factors are important causes of MDA in women. Although many genes and mutations have been found to be associated with the pathogenesis of MDA, in most cases, the genetic pathogenic factors of MDA are still unknown. Methods We first analyzed the three sisters using low coverage whole‐genome sequencing. Then whole‐exome sequencing was carried out in each patient. The identified sequence variant was confirmed by Sanger sequencing. In silico pathogenicity analysis and conservative analysis of the mutation site were also performed. Protein structural modeling was used to analyze the effect of the mutated amino acid. Results We first analyzed the three sisters with septate uterus using low coverage whole‐genome sequencing, but no possible pathogenic copy number variation was found. Then whole‐exome sequencing was performed on the three sisters, and a rare homozygous variant, CDC42BPB:c.2012G>A:p.R671Q, was identified. All three patients were found with this variant. Sanger sequencing validated that this variant was segregated within the family. In silico pathogenicity analysis and conservative analysis of the mutation site suggested that the variant might be damaging. Protein structural analysis suggested that R671Q might weaken the electrostatic potential of this region, which may be a significant regulation target or protein interaction surface of CDC42BPB. Conclusion We demonstrated that CDC42BPB genetic variant might be potentially associated with the pathogenesis of MDA.
- 10 February 2020
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 46 (5) , 684-693
Sequence variant in the CDC42BPB gene is potentially associated with Mullerian duct anomalies
Aim Mullerian duct anomalies (MDA) are common female genital tract malformations. Genetic and environmental factors are important causes of MDA in women. Although many genes and mutations have been found to be associated with the pathogenesis of MDA, in most cases, the genetic pathogenic factors of MDA are still unknown. Methods We first analyzed the three sisters using low coverage whole‐genome sequencing. Then whole‐exome sequencing was carried out in each patient. The identified sequence variant was confirmed by Sanger sequencing. In silico pathogenicity analysis and conservative analysis of the mutation site were also performed. Protein structural modeling was used to analyze the effect of the mutated amino acid. Results We first analyzed the three sisters with septate uterus using low coverage whole‐genome sequencing, but no possible pathogenic copy number variation was found. Then whole‐exome sequencing was performed on the three sisters, and a rare homozygous variant, CDC42BPB:c.2012G>A:p.R671Q, was identified. All three patients were found with this variant. Sanger sequencing validated that this variant was segregated within the family. In silico pathogenicity analysis and conservative analysis of the mutation site suggested that the variant might be damaging. Protein structural analysis suggested that R671Q might weaken the electrostatic potential of this region, which may be a significant regulation target or protein interaction surface of CDC42BPB. Conclusion We demonstrated that CDC42BPB genetic variant might be potentially associated with the pathogenesis of MDA.
- Open Access
- 1 January 2015
- Published by Wiley in BioMed Research International
- Vol. 2015, 1-7
Identification of a Novel Heterozygous Missense Mutation in theCACNA1FGene in a Chinese Family with Retinitis Pigmentosa by Next Generation Sequencing
Background.Retinitis pigmentosa (RP) is an inherited retinal degenerative disease, which is clinically and genetically heterogeneous, and the inheritance pattern is complex. In this study, we have intended to study the possible association of certain genes with X-linked RP (XLRP) in a Chinese family.Methods.A Chinese family with RP was recruited, and a total of seven individuals were enrolled in this genetic study. Genomic DNA was isolated from peripheral leukocytes, and used for the next generation sequencing (NGS).Results.The affected individual presented the clinical signs of XLRP. A heterozygous missense mutation (c.1555C>T, p.R519W) was identified by NGS in exon 13 of theCACNA1Fgene on X chromosome, and was confirmed by Sanger sequencing. It showed perfect cosegregation with the disease in the family. The mutation at this position in theCACNA1Fgene of RP was found novel by database searching.Conclusion.By using NGS, we have found a novel heterozygous missense mutation (c.1555C>T, p.R519W) inCACNA1Fgene, which is probably associated with XLRP. The findings might provide new insights into the cause and diagnosis of RP, and have implications for genetic counseling and clinical management in this family.
- 1 January 2015
- Published by Wiley in BioMed Research International
- Vol. 2015, 1-7
Open AccessIdentification of a Novel Heterozygous Missense Mutation in theCACNA1FGene in a Chinese Family with Retinitis Pigmentosa by Next Generation Sequencing
Background.Retinitis pigmentosa (RP) is an inherited retinal degenerative disease, which is clinically and genetically heterogeneous, and the inheritance pattern is complex. In this study, we have intended to study the possible association of certain genes with X-linked RP (XLRP) in a Chinese family.Methods.A Chinese family with RP was recruited, and a total of seven individuals were enrolled in this genetic study. Genomic DNA was isolated from peripheral leukocytes, and used for the next generation sequencing (NGS).Results.The affected individual presented the clinical signs of XLRP. A heterozygous missense mutation (c.1555C>T, p.R519W) was identified by NGS in exon 13 of theCACNA1Fgene on X chromosome, and was confirmed by Sanger sequencing. It showed perfect cosegregation with the disease in the family. The mutation at this position in theCACNA1Fgene of RP was found novel by database searching.Conclusion.By using NGS, we have found a novel heterozygous missense mutation (c.1555C>T, p.R519W) inCACNA1Fgene, which is probably associated with XLRP. The findings might provide new insights into the cause and diagnosis of RP, and have implications for genetic counseling and clinical management in this family.